The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortalization (Review)

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 499-507

  Band, Vimla ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell immortalization; Mammary epithelial; p53 gene; Retinoblastoma gene

Indexed keywords

PROTEASOME; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER; UBIQUITIN;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL IMMORTALIZATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 0031906947     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Farber E: The multistep nature of cancer development. Cancer Res 44: 4217-4223, 1984.
2. Klein G and Klein E: Evolution of tumors and the impact of molecular oncology. Nature 315: 190-195, 1985.
3. Lynch HT, Conway T, Watson P, Schreiman J and Fitzgibbons RJ: Extremely early onset hereditary breast cancer (HBC): surveillance management implications. Nebr Med J 73: 97-100, 1988.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Sone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
5. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE and Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q12-13. Science 265: 2088-2090, 1994.
6. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
7. Fung YKT, Murphree AL, T'Ang A, Qian J, Hinrichs SH and Benedict WF: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236: 1657-1661, 1987.
8. Schubert EL, Hansen MF and Strong LC: The retinoblastoma gene and its significance. Ann Med 26: 177-184, 1994.
9. Cox LA, Chen G and Lee EY-HP: Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res Treat 32: 19-38, 1994.
10. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P and Lee W-H: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218-221, 1988.
11. T'Ang A, Varley JM, Chakraborty S, Murphree AL and Fung Y-K: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263-266, 1988.
12. Dutrillaux B, Gerbault-Seureau M and Zafrani B: Characterization of chromosomal anomalies in human breast cancer. Cancer Genet Cytogenet 49: 203-217, 1990.
13. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
14. Linzer DIH, Maltzman W and Levine AJ: The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology 98: 303-318, 1979.
15. Lane DP and Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263, 1979.
16. Nagarajan M, Bowman M, Rigby L, Rhim JS and Sukumar S (eds): p53 a direct target of mutational activation by chemical carcinogens. In: Neoplastic Transformation in Human Cell culture. Rhim JS and Dristchilo A, pp135-139, 1991.
17. Jenkins JR, Rudge K and Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312: 651-654, 1984.
18. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
19. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-356, 1994.
20. Prives C: How loops, β sheets, and α helices help us to understand p53. Cell 78: 543-546, 1994.
21. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and Friend SH: Germ-line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-1238, 1990.
22. Srivastava S, Zou Z, Pirollo K, Blattner W and Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749, 1990.
23. Wazer DE, Liu X-L, Chu Q, Gao Q and Band V: Immortalization of distinct human mammary epithelial cell types by human papilloma virus-16 E6 or E7. Proc Natl Acad Sei USA 92: 3687-3691, 1995.
24. Gao Q, Hauser SH, Liu X-L, Wazer DE, Madoc-Jones H and Band V: Mutant p53-induced immortalization of primary human mammary epithelial cells. Cancer Res 56: 3129-3133, 1996.
25. Bartek J, Bartkova J, Kyprianou N, Lalani EN, Staskova Z, Shearer M, Chang S and Taylor-Papadimitriou J: Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with recombinant retrovirus. Proc Natl Acad Sci USA 88: 3520-3524, 1991.
26. Stampfer MR and Bartley JC: Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo(a)pyrene. Proc Natl Acad Sci USA 82: 2394-2398, 1985.
27. Clark R, Stampfer MR, Milley R, O'Rourke E, Walen KH, Kriegler M, Kopplin J and McCormick F: Transformation of human mammary epithelial cells by oncogenic retroviruses. Cancer Res 48: 4689-4694, 1988.
28. Pierce JH, Arnstein P, Di Marco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP and Aaronson SA: Oncogenic potential of erbB2 in human mammary epithelial cells. Oncogene 6: 1189-1194, 1991.
29. Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C, Esselman WJ and Welsch CW: Increased expression of specific protein tyrosine phosphatases in human breast epilhelial cells neoplastically transformed by the neu oncogene. Cancer Res 53: 2272-2278, 1993.
30. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990.
31. Briand P, Petersen OW and van Deurs B: A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol 23: 181-188, 1987.
32. Shay JW, Tomlinson G, Piatyszek MA and Gollahon LS: Spontaneous IH vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 15: 425-432, 1995.
33. Hammond SL, Ham RG and Stampfer MR: Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci USA 81: 5435-5439, 1984.
34. Band V and Sager R: Distinctive traits of normal and tumorderived human mammary epithelial celts expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci USA 86: 1249-1253, 1989.
35. Kennedy MJ and Abeloff MD: Management of locally recurrent breast cancer. Cancer 71: 2395-2409, 1992.
36. Fisher ER, Anderson S, Redmond C and Fisher B: Ipsilaterial breast tumor recurrence and survival following lumpectomy and irradiation: pathological findinss from NSABP protocol B-06. Semin Surg Oncol 8: 161-166, 1992.
37. Sager R: Resistance of human cells to oncogenic transformation. Cancer Cells 2: 487-494, 1984.
38. Rhim JS, Dritschilo A and Barrett JC (eds): Comparison of human versus rodent cell transformation: importance of cell aging. In: Neoplastic Transformation in Human Cell Culture. Humana Press, New York, pp3-13, 1991.
39. Band V, Zajchowski D, Kulesa V and Sager R: Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA 87: 463-467, 1990.
40. Zur Hausen H: Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Topics Micro Immunol 186: 131-156, 1994.
41. Munger K, Phelps WC, Bubb V, Howley PM and Schlegel R: The E6 and E7 genes of the human papilloma virus type 16 together are necessary and sufficient for the transformation of primary human keratinocytes. J Virol 63: 4417-4421, 1989.
42. Barbosa MS and Schlegel R: The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4: 1529-1532, 1989.
43. Band V, De Caprio JA, Delmolino L, Kulesa V and Sager R: Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 65: 6671-6676, 1991.
44. Band V, Dalai S, Delmolino L and Androphy EJ: Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 12: 1847-1852, 1993.
45. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
46. Crook T, Tidy JA and Vousden KH: Degradation of p53 can be targeted by HPV-E6 sequences distinct from those required for p53 binding and transactivation. Cell 67: 547-556, 1991.
47. Kern SE: p53: tumor suppression throuch control of the cell cycle. Gastroenterology 106: 1708-1711, 1994.
48. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
49. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
50. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T and van Dyke T: p53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711, 1994.
51. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
52. Delmolino L, Band H and Band V: Expression and stability of p53 protein in normal human mammary epithelial cells. Carcinogenesis 14: 827-832, 1993.
53. Dalal S, Gao Q, Androphy EJ and Band V: Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 70: 683-688, 1996.
54. Wazer DE, Chu Q, Liu X-L, Gao Q, Safaii H and Band V: Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol Cell Biol 14: 2468-2478, 1994.
55. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R and Minna JD: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194-6198, 1991.
56. Davidoff AM, Kerns B-JM, Pence JC, Marks JR and Iglehart JD: p53 alterations in all stases of breast cancer. J Surg Oncol 48: 260-267, 1991.
57. Liu X-L, Band H, Gao Q, Wazer DE, Chu Q and Band V: Tumor cell-specific loss of p53 protein in a unique in vitro model of human breast tumor progression. Carcinogenesis 15: 1969-1973, 1994.
58. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pci H, He M, Wold L, Melton LJ, Ballard D, Conway K and Liu ET: p53 mutations in benign breast tissue. J Clin Oncol 13: 2293-2300, 1995.
59. Chen J-Y, Funk WD, Wright WE, Shay JW and Minna JD: Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-2166, 1993.
60. Cao Y-A, Gao Q, Wazer DE and Band V: Abrogation of wildtype p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cancer Res 57: 5584-5589, 1997.
61. Gollahon LS and Shay JW: Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Oncogene 12: 715-725, 1996.
62. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Apclla E and Groncborn AM: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265: 386-391, 1994.
63. Bargonctti J, Friedman P, Kern S, Vogelstein B and Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV 40 origin of replication. Cell 65: 1083-1091, 1991.
64. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830, 1992.
65. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ and Shenk T: Wild-type p53 binds to , the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89: 12028-12032, 1992.
66. Mack DH, Vartikar J, Pipas JM and Laimonis LA: Specific repression of TATA-mcdiated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283, 1993.
67. Sabbatini P, Chiou S-K, Rao L and White E: Modulation of p53-mediated transcriptional repression and apoptosis by adenovirus E1B 19K protein. Mol Cell Biol 15: 1060-1070, 1995.
68. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
69. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ Jr: A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71: 587-597, 1992.
70. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
71. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
72. Gaelles C, Helmberg A and Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
73. Canman CE, Gilmer TM, Coutts SB and Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-611, 1995.
74. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
75. Milner J and Medcalf EA: Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774, 1991.
76. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine AJ: Gain of function mutations in p53. Nat Genet 4: 42-46, 1993.
77. Lin J, Teresky AK and Levine AJ: Two critical Hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10: 2387-2390, 1995.
78. Chen Y, Chen P-L and Lee W-H: Hot-spot p53 mutants interacts specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 14: 6764-6772, 1994.
79. Dyson N, Howley PM, Munger K and Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the rctinoblastoma gene product. Science 243: 934-937, 1989.
80. Banks L, Edmonds C and Vousden KH: Ability of the HPV 16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transformine activity. Oncogenc 5: 1283-1389, 1990.
81. Ludlow JW, Shon J, Pipas JM, Livingston DM and Decaprio JA: The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 60: 387-396, 1990.
82. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
83. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
84. Lees JA, Saito M, Vidai M, Valentine M, Look T, Harlow ED, Dyson N and Helin K: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13: 7813-7825, 1993.
85. Davies R, Hicks R, Crook T, Morris J and Vousden K: Human papillomavirus type 16 E7 associates with histone H1 kinasc and with p 107 through sequences necessary for transformation. J Virol 67: 2521-2528, 1993.
86. Phelps WC, Munger K, Yee CL, Barnes JA and Howley PM: Structure function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66: 2418-2427, 1992.
87. Pagano M, Tam SW, Theodoras AM, Beer-Romano P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M: Role of the ubiquitin proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 269: 682-685, 1995.
88. Maki CG, Huibregtse JM and Howley PM: In vitro ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56: 2649-2654, 1996.
89. Weissman AM: Regulating protein degradation by ubiquitination. Immunol Today 18: 189-198, 1997.
90. Beer-Romero P, Glass S and Rolfe M: Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 14: 595-602, 1997.
91. Chowdary DR, Dermody JJ, Jha KK and Ozer HL: Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14: 1997-2003, 1994.
92. Boyer SN, Wazer DE and Band V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-protcasome pathway. Cancer Res 56: 4620-4624, 1996.
93. Demers GW, Foster SA, Halbert CL and Galloway DA: Growth arrest by induction of p53 in DNA damaged kcratinocytcs is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 91: 4382-4386, 1994.
94. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O and Reznikoff C: Increased p16 levels correlate with pRb alterations in human uroepithelial cells. Cancer Res 55: 493-497, 1995.
95. Jones DL and Munger K: Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71: 2905-2912, 1997.
96. Scheffner M, Munger K, Huibregtse JM and Howley PM: Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion protein. EMBO J 11: 2425-2431, 1992.
97. Liu X-L, Wazer DE, Watanabe K and Band V: Identification of a novel serine protease-like gene the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371-3379, 1996.